Most Read Articles
22 Jan 2018
In a symposium chaired by Dr Yoon-Sim Yap of the National Cancer Centre Singapore, renowned regional and international experts in the field of breast cancer, Dr Yen-Shen Lu from Taiwan and Professor Nadia Harbeck from Germany, joined her in providing insights on the current treatment landscape of hormone receptor-positive (HR+) advanced breast cancer. In their respective sessions, they each highlighted new therapeutic options including the optimal use of dual blockade therapy for oestrogenreceptor-positive (ER+) advanced breast cancer for patients in Asia. 
Pearl Toh, 19 Dec 2016
Osimertinib, a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI), showed significantly greater efficacy than platinum-pemetrexed therapy in advanced non-small cell lung cancer (NSCLC) patients positive for T790M mutation, including those with central nervous system (CNS) metastases, according to data from the AURA3* trial.
Rachel Soon, 06 Feb 2017

An RM6 million shortfall may delay the development of the first immunotherapeutic vaccine to target oral cancers, according to a local team of scientists.

Naomi Adam, 01 Apr 2014

Colorectal cancer (CRC) is one of the most common cancers worldwide and its incidence is rising among Asians. Long-term survival outcomes are poor for CRC because patients often remain undiagnosed until the disease has reached an advanced stage. Panitumumab, a human IgG2 monoclonal antibody with high binding affinity for epidermal growth factor receptors, has shown encouraging results in the treatment of metastatic CRC (mCRC).

Accelerated elozutumab infusion safe for multiple myeloma

08 Sep 2017

Accelerated administration of elotuzumab for multiple myeloma (MM) or relapsed/refractory MM (RRMM) is safe and produces no grade 3 or 4 infusion reactions (IRs), a phase 2 study shows.

Investigators involved 70 adults with active and newly diagnosed MM or RRMM (median age 67.5 years). Of these, 47 percent (n=33) had received prior treatments for MM, the most common of which was bortezomib (41 percent).

Infusion rate of the first dose of elotuzumab during cycle 1 was increased from 0.5 to 2 mL/min in the absence of IRs. Rates were increased from 3 to 4 mL/min during dose 2 and to mL/min for all succeeding doses. Of all infusions, 87 percent (n=968) were delivered at the maximum rate of 5 mL/min.

There were no reported cases of the primary outcome of grade 3 or 4 IRs by the end of cycle 2. Only two IRs were reported, both of which manifested during the 2 mL/min infusion rate. One patient experienced a nonspecific grade 2 infusion-related reaction, while the other had a grade 1 pyrexia.

Infusion was interrupted only in the case of the grade 2 IR but was resumed after resolution. No treatments were discontinued due to IRs.

The most common adverse event (AE) was infection which was observed in 60 percent (n=42) of the participants. This was followed by fatigue (50 percent; n=35) and diarrhoea (31 percent; n=22). Eight cases of grade 4 AEs were reported and 13 patients discontinued treatment because of AEs.

A total of 27 patients experienced severe AEs, the most common of which were pneumonia and atrial fibrillation which were observed in three patients each. There was a total of five deaths caused by disease progression, fatal bleeding, respiratory failure and ischaemic bowel syndrome.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Oncology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
22 Jan 2018
In a symposium chaired by Dr Yoon-Sim Yap of the National Cancer Centre Singapore, renowned regional and international experts in the field of breast cancer, Dr Yen-Shen Lu from Taiwan and Professor Nadia Harbeck from Germany, joined her in providing insights on the current treatment landscape of hormone receptor-positive (HR+) advanced breast cancer. In their respective sessions, they each highlighted new therapeutic options including the optimal use of dual blockade therapy for oestrogenreceptor-positive (ER+) advanced breast cancer for patients in Asia. 
Pearl Toh, 19 Dec 2016
Osimertinib, a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI), showed significantly greater efficacy than platinum-pemetrexed therapy in advanced non-small cell lung cancer (NSCLC) patients positive for T790M mutation, including those with central nervous system (CNS) metastases, according to data from the AURA3* trial.
Rachel Soon, 06 Feb 2017

An RM6 million shortfall may delay the development of the first immunotherapeutic vaccine to target oral cancers, according to a local team of scientists.

Naomi Adam, 01 Apr 2014

Colorectal cancer (CRC) is one of the most common cancers worldwide and its incidence is rising among Asians. Long-term survival outcomes are poor for CRC because patients often remain undiagnosed until the disease has reached an advanced stage. Panitumumab, a human IgG2 monoclonal antibody with high binding affinity for epidermal growth factor receptors, has shown encouraging results in the treatment of metastatic CRC (mCRC).